BVT Put 94 ABT 20.09.2024/ DE000VM3MC47 /
2024-07-09 8:54:51 AM | Chg.+0.031 | Bid3:48:57 PM | Ask3:48:57 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.130EUR | +31.31% | 0.139 Bid Size: 132,000 |
0.149 Ask Size: 132,000 |
Abbott Laboratories | 94.00 USD | 2024-09-20 | Put |
GlobeNewswire
06-06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
05-09
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
03-25
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
03-15
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
2023-11-14
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
2023-10-19
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
2023-10-10
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
2023-10-02
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
GlobeNewswire
2023-09-06
Endexx Corporation Appoints Ahmed Itani to Director of Marketing of HYLA in The Middle East Region